BioTuesdays

Category - News

Arvinas

Roth starts Arvinas at buy; PT $35

Roth Capital Partners initiated coverage of Arvinas (NASDAQ:ARVN) with a “buy” rating and $35 price target. The stock closed at $28.38 on Nov. 13. Analyst Zegbeh Jallah writes that Arvinas is one of the leaders in the...

GlycoMimetics

Roth resumes coverage of GlycoMimetics at buy; PT $12

Roth Capital Partners resumed coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and price target of $12. The stock closed at $6.26 on Nov. 13. Analyst Zegbeh Jallah writes that following an August announcement...

Bicycle Therapeutics

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

Harpoon Therapeutics

Roth starts Harpoon Therapeutics at buy; PT $25

Roth Capital Partners launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and price target of $25. The stock closed at $13.51 on Nov. 13. Analyst Zegbeh Jallah writes that Harpoon has a next...

Cerus

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

Subscribe

Sign up to our weekly BioTuesdays newsletter.